Photocure Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Photocure şirketinin kazançları yıllık ortalama -22.8% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 13.1% oranında artan oldu. Gelirler yıllık ortalama 16.7% oranında artan oldu. Photocure şirketinin öz sermaye getirisi 2.6% olup, net marjı 2.5% dir.

Anahtar bilgiler

-22.8%

Kazanç büyüme oranı

-21.7%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	12.4%
Gelir büyüme oranı	16.7%
Özkaynak getirisi	2.6%
Net Marj	2.5%
Sonraki Kazanç Güncellemesi	13 Nov 2024

Yakın geçmiş performans güncellemeleri

We Think Photocure's (OB:PHO) Robust Earnings Are Conservative

Aug 14

Recent updates

Analyst Estimates: Here's What Brokers Think Of Photocure ASA (OB:PHO) After Its Second-Quarter Report

Aug 14

We Think Photocure (OB:PHO) Can Stay On Top Of Its Debt

Aug 12

Do Institutions Own Photocure ASA (OB:PHO) Shares?

Feb 11

Photocure ASA's (OB:PHO) Stock Is Going Strong: Have Financials A Role To Play?

Jan 21

The Photocure (OB:PHO) Share Price Is Up 286% And Shareholders Are Boasting About It

Dec 31

We're Not So Sure You Should Rely on Photocure's (OB:PHO) Statutory Earnings

Dec 09

Is Photocure (OB:PHO) Using Too Much Debt?

Nov 19

Gelir ve Gider Dağılımı

Photocure nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OB:PHO Gelir, gider ve kazançlar (NOK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	514	13	355	3
31 Mar 24	512	5	350	2
31 Dec 23	501	1	348	2
30 Sep 23	462	-34	346	2
30 Jun 23	462	-39	342	2
31 Mar 23	418	-62	329	3
31 Dec 22	393	-72	319	3
30 Sep 22	383	-79	307	4
30 Jun 22	364	-76	299	4
31 Mar 22	354	-68	289	5
31 Dec 21	361	-31	275	4
30 Sep 21	364	7	261	7
30 Jun 21	326	9	233	10
31 Mar 21	290	10	214	11
31 Dec 20	256	-22	201	14
30 Sep 20	274	10	178	14
30 Jun 20	285	15	174	13
31 Mar 20	284	19	165	13
31 Dec 19	282	32	160	14
30 Sep 19	216	-23	153	15
30 Jun 19	199	-27	147	16
31 Mar 19	192	-39	140	18
31 Dec 18	182	-37	132	19
30 Sep 18	171	-38	123	23
30 Jun 18	162	-43	170	42
31 Mar 18	156	-31	114	28
31 Dec 17	151	-35	108	33
30 Sep 17	150	-4	103	32
30 Jun 17	149	6	45	13
31 Mar 17	145	29	92	27
31 Dec 16	144	35	90	23
30 Sep 16	140	8	91	25
30 Jun 16	141	3	91	26
31 Mar 16	140	-26	87	30
31 Dec 15	135	-36	84	31
30 Sep 15	126	-58	53	31
30 Jun 15	147	-29	57	31
31 Mar 15	138	-23	59	31
31 Dec 14	129	-25	64	33
30 Sep 14	129	-2	65	33
30 Jun 14	92	-39	65	34
31 Mar 14	89	-50	71	34
31 Dec 13	84	-59	76	34

Kaliteli Kazançlar: PHO yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: PHO geçmişte karlı hale geldi.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: PHO son 5 yılda karlı hale geldi ve kazançlarını yıllık -22.8% oranında artırdı.

Büyüme Hızlandırma: PHO son bir yılda karlı hale geldi, bu da kazanç büyüme oranının 5 yıllık ortalamayla karşılaştırılmasını zorlaştırıyor.

Kazançlar vs. Sektör: PHO son bir yılda karlı hale geldi ve bu durum, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 4.5% ) karşılaştırılmasını zorlaştırıyor.

Özkaynak Getirisi

Yüksek ROE: PHO 'nin Özsermaye Getirisi ( 2.6% ) düşük olarak değerlendiriliyor.

Photocure Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

We Think Photocure's (OB:PHO) Robust Earnings Are Conservative

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Third quarter 2023 earnings released: kr0.18 loss per share (vs kr0.37 loss in 3Q 2022)

Recent updates

Consensus EPS estimates fall by 17%

We Think Photocure's (OB:PHO) Robust Earnings Are Conservative

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase from loss to kr0.019 profit

Photocure ASA's (OB:PHO) P/S Still Appears To Be Reasonable

Photocure ASA Announces Board Appointments

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Photocure ASA Reiterates Financial Guidance for the Year 2024

Consensus EPS estimates fall from profit to kr0.58 loss

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Consensus EPS estimates increase by 50%, revenue downgraded

Price target decreased by 7.0% to kr86.00

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast breakeven date pushed back to 2025

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA's (OB:PHO) 26% Jump Shows Its Popularity With Investors

Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China

Third quarter 2023 earnings released: kr0.18 loss per share (vs kr0.37 loss in 3Q 2022)

Photocure ASA Announces Change of Board Composition

Director recently bought kr6.5m worth of stock

Potential Upside For Photocure ASA (OB:PHO) Not Without Risk

Price target decreased by 10.0% to kr90.00

Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

Insufficient new directors

Consensus estimates of losses per share improve by 15%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Time To Worry? Analysts Just Downgraded Their Photocure ASA (OB:PHO) Outlook

Price target decreased by 7.7% to kr120

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy

Price target decreased to kr125

Third quarter 2022 earnings released: kr0.37 loss per share (vs kr0.27 loss in 3Q 2021)

Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc

PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S

Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology

Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to kr135

Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States

Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022.

President & CEO exercised options to buy kr10m worth of stock.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S

Consensus EPS estimates fall to -kr0.53

Third quarter 2021 earnings released: kr0.27 loss per share (vs kr0.23 loss in 3Q 2020)

Insider exercised options to buy kr2.8m worth of stock.

Consensus EPS estimates fall to -kr0.53

Analyst Estimates: Here's What Brokers Think Of Photocure ASA (OB:PHO) After Its Second-Quarter Report

We Think Photocure (OB:PHO) Can Stay On Top Of Its Debt

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology

Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)

President & CEO exercised options to buy kr2.8m worth of stock.

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020.

Photocure ASA Suspends Guidance for 2023